Covid-19 (Temas de Saúde Pública)
Opinião | Causalidade ou confusão: por que os grupos controle são fundamentais para caracterizar a “long COVID” – “Muitos dos sintomas autorrelatados, como cefaleias intermitentes ou cansaço, são inespecíficos e prevalentes na população geral.”
18 Jun, 2021 | 10:37hCausation or confounding: why controls are critical for characterizing long COVID – Nature
Estudo mostra que a taxa de reinfecção por COVID-19 é inferior a 1% em pacientes que tiveram doença grave.
18 Jun, 2021 | 10:35hEstudo original: Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing – Clinical Infectious Diseases
Agora, o CDC chama a variante Delta do coronavírus de “variante de preocupação”.
17 Jun, 2021 | 11:02hCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Diretriz: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Comentário no Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
[Comunicado de imprensa – Ainda não publicado] CureVac falha como vacina contra COVID-19 em estudo, com 47% de eficácia.
17 Jun, 2021 | 11:01hCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Ver também: CureVac’s COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech – Insider
Comunicado de imprensa: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Comentário no Twitter (fio – clique para saber mais)
Bad new for CureVac's vaccine: it didn't make it over the efficacy bar in its 2nd interim analysis – only 47%. Not bad enough to be out for the count – it's 134 events (symptomatic Covid-19) & final is at 185 – but ….1/2 https://t.co/4GsLzgP7AT HT @noviceprize @megtirrell
— Hilda Bastian, PhD (@hildabast) June 16, 2021
Série de casos | 7 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 11:00hMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:58hComentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Miocardite sintomática aguda em 7 adolescentes após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:57hRelacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
De acordo com um novo relatório, quase 25% dos pacientes que tiveram COVID-19 desenvolvem sintomas de longa duração.
16 Jun, 2021 | 10:55hAlmost 25% of COVID-19 Patients Develop Long-Lasting Symptoms, According to a New Report – TIME
Relatório original: A Detailed Study of Patients with Long-Haul COVID – FAIR Health
Comentário no Twitter (fio – clique para saber mais)
📍1 in 4–almost a quarter of people infected develop at least one lingering health problem after 30 days with #COVID19. The most common included pain, breathing trouble, high cholesterol, malaise and/or fatigue and high blood pressure. 🧵 https://t.co/G4uPtnq86A
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
M-A | Distribuição do período de incubação da Covid-19 – “O período médio de incubação da COVID-19 foi de 5,2 a 7,2 dias, e o percentil 95 estaria entre 11 e 14,6 dias.”
16 Jun, 2021 | 10:53hPerspectiva de longo prazo sobre a imunidade à COVID – “Estudos clínicos agora indicam que a imunidade é de longa duração.”
16 Jun, 2021 | 10:52hA long-term perspective on immunity to COVID – Nature